P. Deegen

发表

Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens

M. Friedrich, P. Hoffmann, R. Kischel, 2012, Molecular Cancer Therapeutics.

AMG 757, a Half-Life Extended, DLL3-Targeted Bispecific T-Cell Engager, Shows High Potency and Sensitivity in Preclinical Models of Small-Cell Lung Cancer

E. Lobenhofer, M. Friedrich, T. Raum, 2020, Clinical Cancer Research.

The Immune Evasion Paradox: Immunoevasins of Murine Cytomegalovirus Enhance Priming of CD8 T Cells by Preventing Negative Feedback Regulation

P. Deegen, M. Reddehase, N. Lemmermann, 2008, Journal of Virology.

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

K. Anderson, M. Friedrich, B. Rattel, 2017, Leukemia.

Cytomegalovirus Encodes a Positive Regulator of Antigen Presentation

D. Strand, P. Deegen, M. Wagner, 2006, Journal of Virology.

Activation of hepatic natural killer cells and control of liver-adapted lymphoma in the murine model of cytomegalovirus infection

P. Deegen, M. Reddehase, J. Podlech, 2008, Medical Microbiology and Immunology.

Highly Protective In Vivo Function of Cytomegalovirus IE1 Epitope-Specific Memory CD8 T Cells Purified by T-Cell Receptor-Based Cell Sorting

P. Deegen, M. Reddehase, J. Podlech, 2005, Journal of Virology.

The PSMA-targeting Half-life Extended BiTE Therapy AMG 160 has Potent Antitumor Activity in Preclinical Models of Metastatic Castration-resistant Prostate Cancer

P. Bogner, M. Friedrich, P. Kufer, 2021, Clinical Cancer Research.

Liver Sinusoidal Endothelial Cells Are a Site of Murine Cytomegalovirus Latency and Reactivation

P. Deegen, Hanna-Mari Tervo, M. Reddehase, 2009, Journal of Virology.

Immune Evasion Proteins of Murine Cytomegalovirus Preferentially Affect Cell Surface Display of Recently Generated Peptide Presentation Complexes

P. Deegen, M. Reddehase, N. Lemmermann, 2009, Journal of Virology.

Abstract LB-299: Cynomolgus monkey plasma cell gene signature to quantify thein vivoactivity of a half-life extended anti-BCMA BiTE® for the treatment of multiple myeloma

T. Arvedson, P. Bogner, O. Thomas, 2018, Immunology.

Refinement of strategies for the development of a human cytomegalovirus dense body vaccine

U. Wolfrum, B. Plachter, S. Reyda, 2008, Medical Microbiology and Immunology.

Subdominant CD8 T-Cell Epitopes Account for Protection against Cytomegalovirus Independent of Immunodomination

M. Munks, P. Deegen, A. Hill, 2008, Journal of Virology.

Epitope-specific in vivo protection against cytomegalovirus disease by CD8 T cells in the murine model of preemptive immunotherapy

P. Deegen, M. Reddehase, N. Lemmermann, 2008, Medical Microbiology and Immunology.

Biodistribution and PET Imaging of Labeled Bispecific T Cell–Engaging Antibody Targeting EpCAM

E. D. de Vries, J. Kosterink, M. Friedrich, 2016, The Journal of Nuclear Medicine.

Preclinical evaluation of AMG 160, a next-generation bispecific T cell engager (BiTE) targeting the prostate-specific membrane antigen PSMA for metastatic castration-resistant prostate cancer (mCRPC).

P. Bogner, P. Kufer, T. Raum, 2019, Journal of Clinical Oncology.

Regression of Human Prostate Cancer Xenografts in Mice by AMG 212/BAY2010112, a Novel PSMA/CD3-Bispecific BiTE Antibody Cross-Reactive with Non-Human Primate Antigens

M. Friedrich, P. Hoffmann, R. Kischel, 2012, Molecular Cancer Therapeutics.

AMG 701 induces cytotoxicity of multiple myeloma cells and depletes plasma cells in cynomolgus monkeys.

T. Arvedson, P. Bogner, M. Friedrich, 2020, Blood advances.

BI 836909, a Novel Bispecific T Cell Engager for the Treatment of Multiple Myeloma Induces Highly Specific and Efficacious Lysis of Multiple Myeloma Cells in Vitro and Shows Anti-Tumor Activity in Vivo

M. Friedrich, B. Rattel, O. Thomas, 2015 .

Novel Therapeutic Approach to Improve Hematopoiesis in low risk MDS by Targeting MDSCs with The Fc-engineered CD33 Antibody BI 836858

K. Anderson, Sheng Wei, M. Friedrich, 2017, Leukemia.

Preclinical Assessment of a MUC12-Targeted BiTE (Bispecific T-cell Engager) Molecule

M. Friedrich, B. Rattel, A. Coxon, 2021, Molecular Cancer Therapeutics.

Generation of Half-Life Extended Anti-BCMA Bite® Antibody Construct Compatible with Once-Weekly Dosing for Treatment of Multiple Myeloma (MM)

P. Bogner, O. Thomas, J. Wahl, 2017 .